Quantum Biopharma QNTM Institutional Ownership

Updated Oct 21, 2026

Quantum Biopharma Ltd. (NASDAQ:QNTM) counted 27 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• Together they owned 10.68% of the outstanding stock in Q2 2026, up from 6.54% a quarter earlier.
• Total holdings of QNTM shares rose 63.24% from Q1 2026, and the holder count rose 68.75% from Q2 2025.
• Of the 27 holders, 13 added to their positions, 4 reduced their stakes and 10 left their positions unchanged in Q2 2026.
• Combined, institutional investors held 415.12K shares of QNTM as of Q2 2026, up 160.82K from the prior quarter and up 298.74K from a year earlier.
• AdvisorShares Investments LLC led 13F holders of QNTM with 203.56K shares as of June 30, 2026, or 5.24% of shares outstanding.
• The biggest increases in QNTM positions during Q2 2026 came from AdvisorShares Investments LLC (+94.97K shares), UBS Group AG (+26.17K shares), Steward Partners Investment Advisory, LLC (+23.5K shares), Jane Street Group, LLC (+16.85K shares) and Jones Financial Companies LLLP (+509 shares).
• The largest position reductions in QNTM for Q2 2026 were by Osaic Holdings, Inc. (-80 shares), Mariner, LLC (-59 shares), Marex Group Ltd (-32 shares) and TD Waterhouse Canada Inc. (-14 shares).
• According to Business Quant data, the leading holders of QNTM for Q2 2026 were AdvisorShares Investments LLC (203.56K shares), Jane Street Group, LLC (48.35K shares), Platform Technology Partners (41.12K shares), UBS Group AG (33.41K shares), Steward Partners Investment Advisory, LLC (27.88K shares), Citadel Advisors LLC (15.86K shares), Marex Group Ltd (13.44K shares), Mariner, LLC (10K shares), Lanark Financial, Inc. (7K shares) and Osaic Holdings, Inc. (6.29K shares).